gemfibrozil and Hyperlipoproteinemia studies

Research Excerpts

Excerpt	Relevance	Reference
"In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months."	9.08	A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995)
" We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia."	9.08	Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. ( Angelin, B; Bröijersen, A; Eriksson, M; Hjemdahl, P; Wiman, B, 1996)
"Nineteen adult patients with type III hyperlipoproteinemia (HLP) and homozygosity for apolipoprotein (apo) E2 were treated with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor simvastatin (20 or 40 mg per day) alone or in combination with the fibrate derivative gemfibrozil (450 mg per day) during a 30-week outpatient study."	9.07	The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. ( Eichinger, M; Feussner, G; Ziegler, R, 1992)
"To compare the efficacy and tolerability of Gemfibrozil and Bezafibrate in patients with hyperlipoproteinemia, types IIa, IIb and IV."	9.07	[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. ( Bergmann, S; Fücker, K; Gross, P; Hanefeld, M; Hora, C; Julius, U, 1992)
"The effects of gemfibrozil on serum lipids and apolipoproteins were investigated in 60 male survivors of myocardial infarction (MI) (age range 29-48 years, mean 44)."	9.05	Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. ( Ehnholm, C; Kaukola, S; Mälkönen, M; Manninen, V, 1981)
"Gemfibrozil treatment produced a marked reduction in plasma triglyceride (51%, P = 0."	6.66	Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. ( Cheung, AK; Ellis-Benigni, K; Groggel, GC; Wilson, DE, 1989)
"In a double-blind, randomized crossover study, 29 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipoproteinemia were treated with gemfibrozil (1,200 mg/d) or simvastatin (10 mg/d) for 4 months."	5.08	A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. ( Johansson, J; Lithell, H; Ohrvall, M; Vessby, B, 1995)
" We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia."	5.08	Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. ( Angelin, B; Bröijersen, A; Eriksson, M; Hjemdahl, P; Wiman, B, 1996)
"Nineteen adult patients with type III hyperlipoproteinemia (HLP) and homozygosity for apolipoprotein (apo) E2 were treated with the 3-hydroxy-3-methyl glutaryl coenzyme A (HMG CoA) reductase inhibitor simvastatin (20 or 40 mg per day) alone or in combination with the fibrate derivative gemfibrozil (450 mg per day) during a 30-week outpatient study."	5.07	The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. ( Eichinger, M; Feussner, G; Ziegler, R, 1992)
"To compare the efficacy and tolerability of Gemfibrozil and Bezafibrate in patients with hyperlipoproteinemia, types IIa, IIb and IV."	5.07	[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. ( Bergmann, S; Fücker, K; Gross, P; Hanefeld, M; Hora, C; Julius, U, 1992)
"The effects of gemfibrozil on serum lipids and apolipoproteins were investigated in 60 male survivors of myocardial infarction (MI) (age range 29-48 years, mean 44)."	5.05	Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. ( Ehnholm, C; Kaukola, S; Mälkönen, M; Manninen, V, 1981)
"Treatment with gemfibrozil, compared with placebo, significantly reduced fasting plasma triglycerides (difference from placebo +/- SE; -50."	2.71	Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. ( Berneis, KK; Rizzo, M; Superko, HR; Williams, PT; Wood, PD, 2005)
"Gemfibrozil treatment produced a marked reduction in plasma triglyceride (51%, P = 0."	2.66	Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. ( Cheung, AK; Ellis-Benigni, K; Groggel, GC; Wilson, DE, 1989)
"In a single-blind study the lipid-lowering drug gemfibrozil was compared at fixed dosage of 1600 mg daily with placebo and other drugs (mainly clofibrate) over a nine month period in 33 patients with hyperlipidaemia."	2.65	The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. ( Nye, ER; Sutherland, WH; Temple, Wa, 1980)
"The metabolic syndrome is characterized by atherogenic dyslipidemia (elevated triglycerides, increased small dense low-density lipoproteins, and decreased high-density lipoproteins), hypertension, insulin resistance and obesity."	2.41	Treatment of dyslipoproteinemia in the metabolic syndrome. ( Fenselau, S; Schrezenmeir, J; Steinmetz, A, 2001)
"A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction."	1.30	Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997)
"Eruptive and tubero-eruptive xanthomas arising at the site of previous minor skin injury are described in two patients with type IV and type III hyperlipidemia, respectively."	1.27	Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports. ( Davignon, J; Roederer, G; Xhignesse, M, 1988)
"Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia."	1.27	Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986)
" It was concluded that the long-term administration of this compound did not show adverse effects on the hepatocyte in hyperlipoproteinemia."	1.26	Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. ( Buchanan, RA; De La Iglesia, FA; Lewis, JE; Marcus, EL; McMahon, G, 1982)

Timeframe	Studies, this research(%)	All Research%
pre-1990	18 (56.25)	18.7374
1990's	11 (34.38)	18.2507
2000's	3 (9.38)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Trial			Phase	Enrollment	Study Type	Start Date	Status
Estudio clínico Fase III Para Evaluar la Eficacia terapéutica en Pacientes Mexicanos Con Dislipidemia Mediante el Uso vía Oral de L-Carnitina + Atorvastatina Comparado Con Atorvastatina[NCT03696940]			Phase 3	120 participants (Actual)	Interventional	2018-05-28	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation, 1984, Volume: 69, Issue:5 Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl	1984
Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. The American journal of cardiology, 1998, Apr-01, Volume: 81, Issue:7 Topics: Animals; Cholesterol, LDL; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hydroxymethylg	1998
Treatment of dyslipoproteinemia in the metabolic syndrome. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2001, Volume: 109, Issue:4 Topics: Arteriosclerosis; Clofibric Acid; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans;	2001
Drug treatment of dyslipoproteinemia. Endocrinology and metabolism clinics of North America, 1990, Volume: 19, Issue:2 Topics: Bile Acids and Salts; Clofibrate; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans;	1990
Pathogenesis and management of lipoprotein disorders. The New England journal of medicine, 1985, May-16, Volume: 312, Issue:20 Topics: Abetalipoproteinemia; Adolescent; Adult; Aged; Child; Child, Preschool; Cholestyramine Resin; Chylom	1985

Article	Year
Gemfibrozil reduces small low-density lipoprotein more in normolipemic subjects classified as low-density lipoprotein pattern B compared with pattern A. The American journal of cardiology, 2005, Nov-01, Volume: 96, Issue:9 Topics: Adult; Aged; Biomarkers; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hy	2005
Clinical results with gemfibrozil. The American journal of cardiology, 1983, Aug-22, Volume: 52, Issue:4 Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Gemfibrozil; Humans; Hype	1983
Influence of gemfibrozil on high-density lipoproteins. The American journal of cardiology, 1983, Aug-22, Volume: 52, Issue:4 Topics: Animals; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Ag	1983
The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate. The New Zealand medical journal, 1980, Nov-12, Volume: 92, Issue:671 Topics: Adult; Aged; Cholesterol; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipoprotei	1980
Hyperlipoproteinemia, atherosclerosis and gemfibrozil. Angiology, 1982, Volume: 33, Issue:9 Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypo	1982
Gemfibrozil in the treatment of dyslipidaemias in middle-aged male survivors of myocardial infarction. Acta medica Scandinavica, 1981, Volume: 209, Issue:1-2 Topics: Adult; Apolipoproteins; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Gemfibrozil; Hum	1981
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia. Metabolism: clinical and experimental, 1995, Volume: 44, Issue:2 Topics: Aged; Body Weight; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Gemfibroz	1995
Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arteriosclerosis, thrombosis, and vascular biology, 1996, Volume: 16, Issue:4 Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fibrinolysis; Gemfibrozil; Humans; Hyperlipopr	1996
A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin. Atherosclerosis, 1997, Mar-21, Volume: 129, Issue:2 Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cross-Over Studies; Dietary Fats; Gemfibro	1997
A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis, 2002, Volume: 162, Issue:1 Topics: Aged; Apolipoproteins; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Double-Blind	2002
The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia. The Clinical investigator, 1992, Volume: 70, Issue:11 Topics: Adult; Apolipoprotein E2; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Combined Modality Therap	1992
[Different effects of fibrates on the lipoprotein profile. Comparison of the effectiveness of gemfibrozil and bezafibrate in various types of hyperlipoproteinemia]. Fortschritte der Medizin, 1992, Dec-20, Volume: 110, Issue:35-36 Topics: Adult; Aged; Bezafibrate; Cholesterol; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipoprote	1992
Treatment of nephrotic hyperlipoproteinemia with gemfibrozil. Kidney international, 1989, Volume: 36, Issue:2 Topics: Adult; Aged; Apolipoproteins; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creat	1989
Helsinki Heart Study. New perspectives in the prevention of coronary heart disease. Drugs, 1988, Volume: 36 Suppl 3 Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Double-Blind	1988

Article	Year
Effects of gemfibrozil on serum lipids. The American journal of medicine, 1983, May-23, Volume: 74, Issue:5A Topics: Adult; Aged; Double-Blind Method; Drug Evaluation; Female; Gemfibrozil; Humans; Hyperlipoproteinemia	1983
Consensus conference: Treatment of hypertriglyceridemia. JAMA, 1984, Mar-02, Volume: 251, Issue:9 Topics: Body Weight; Cardiovascular Diseases; Clofibrate; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipopro	1984
Light and electron microscopy of liver in hyperlipoproteinemic patients under long-term gemfibrozil treatment. Atherosclerosis, 1982, Volume: 43, Issue:1 Topics: Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Liver; Long-Term Care; Microscopy,	1982
Nutritional & pharmacologic management of hyperlipoproteinemia. Angiology, 1982, Volume: 33, Issue:9 Topics: Cholesterol; Cholesterol, Dietary; Clofibrate; Dietary Fats; Gemfibrozil; Humans; Hyperlipoproteinem	1982
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. Chest, 1997, Volume: 112, Issue:4 Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem	1997
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet (London, England), 1998, Sep-26, Volume: 352, Issue:9133 Topics: Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Gemfibrozil; Heptanoic Acids; Hum	1998
Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias. The American journal of cardiology, 1992, Jul-01, Volume: 70, Issue:1 Topics: Adult; Aged; Analysis of Variance; Cholesterol; Combined Modality Therapy; Creatine Kinase; Drug The	1992
Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. European journal of clinical pharmacology, 1991, Volume: 40, Issue:1 Topics: Adult; Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Colestipol; Female; Fenofibrate;	1991
[Gemfibrozil in the treatment of hyperlipoproteinemia]. Vnitrni lekarstvi, 1989, Volume: 35, Issue:10 Topics: Adolescent; Adult; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Lipids; Lipoproteins; Male; M	1989
Lipid level alterations in the Helsinki Heart Study. JAMA, 1989, Jan-27, Volume: 261, Issue:4 Topics: Cholesterol, HDL; Coronary Disease; Finland; Gemfibrozil; Humans; Hyperlipoproteinemias; Triglycerid	1989
Eruptive and tubero-eruptive xanthomas of the skin arising on sites of prior injury. Two case reports. JAMA, 1988, Sep-02, Volume: 260, Issue:9 Topics: Adult; Clofibrate; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; M	1988
Medical management of hyperlipidemia and the role of probucol. The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16 Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem	1986
Rational drug therapy of the hyperlipoproteinemias, Part II. Rational drug therapy, 1986, Volume: 20, Issue:10 Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Female; Fish Oils; Gemfibrozil; Human	1986

gemfibrozil and Hyperlipoproteinemia

Research Excerpts

Research

Studies (32)

Authors

Clinical Trials (1)

Trial Overview

Reviews

Trials

Other Studies

Authors	Studies
Superko, HR	1
Berneis, KK	1
Williams, PT	1
Rizzo, M	1
Wood, PD	1
Pickering, JE	2
Samuel, P	1
Glueck, C	1
De La Iglesia, FA	1
Lewis, JE	1
Buchanan, RA	1
Marcus, EL	1
McMahon, G	1
Nye, ER	1
Sutherland, WH	1
Temple, Wa	1
Nash, DT	1
Kaukola, S	1
Manninen, V	2
Mälkönen, M	1
Ehnholm, C	1
Ohrvall, M	1
Lithell, H	1
Johansson, J	1
Vessby, B	1
Bröijersen, A	1
Eriksson, M	1
Wiman, B	1
Angelin, B	1
Hjemdahl, P	1
Nestel, P	1
Simons, L	1
Barter, P	1
Clifton, P	1
Colquhoun, D	1
Hamilton-Craig, I	1
Sikaris, K	1
Sullivan, D	1
Kesten, S	1
Mayne, L	1
Scavuzzo, M	1
Maurer, J	1
Fruchart, JC	1
Brewer, HB	1
Leitersdorf, E	1
Henry, K	1
Melroe, H	1
Huebesch, J	1
Hermundson, J	1
Simpson, J	1
Steinmetz, A	1
Fenselau, S	1
Schrezenmeir, J	1
Schweitzer, M	1
Tessier, D	1
Vlahos, WD	1
Leiter, L	1
Collet, JP	1
McQueen, MJ	1
Harvey, L	1
Alaupovic, P	1
Feussner, G	1
Eichinger, M	1
Ziegler, R	1
Julius, U	1
Hora, C	1
Gross, P	1
Fücker, K	1
Bergmann, S	1
Hanefeld, M	1
Glueck, CJ	1
Oakes, N	1
Speirs, J	1
Tracy, T	1
Lang, J	1
Kłosiewicz-Latoszek, L	1
Szostak, WB	1
Hunninghake, DB	1
Ceska, R	1
Sobra, J	1
Groggel, GC	1
Cheung, AK	1
Ellis-Benigni, K	1
Wilson, DE	1
Huttunen, JK	1
Frick, MH	1
Heinonen, OP	1
Heinsalmi, P	1
Mänttäri, M	1
Romo, M	1
Roederer, G	1
Xhignesse, M	1
Davignon, J	2
Blum, CB	1
Levy, RI	2
Schaefer, EJ	1